Inmed Pharmaceuticals INC 10-Q quarterly reports

InMed Pharmaceuticals reports Q3 2026 financial results, highlighting the wind-down of its BayMedica commercial segment and a focus on its pharmaceutical pipeline.

InMed Pharmaceuticals reported a reduced net loss and increased cash, but faces significant uncertainty from new U.S. legislation impacting its BayMedica subsidiary and ongoing legal disputes, alongside a stated going concern doubt.

InMed Pharmaceuticals Inc. reported an increased net loss for Q1 2026, alongside a going concern warning and a significant legal dispute impacting its commercial segment.

InMed Pharmaceuticals reports a net loss for Q3 2025 and expresses concerns about its ability to continue as a going concern without additional funding.

InMed Pharmaceuticals announces its financial results for the quarter ended December 31, 2024, and provides updates on its pharmaceutical development programs and commercial operations.

InMed Pharmaceuticals reported its financial results for the quarter ended September 30, 2024, while also addressing its Nasdaq listing compliance through a reverse stock split.

InMed Pharmaceuticals released its Q3 2024 financial results, showcasing revenue growth in its commercial segment and advancements in its pharmaceutical research programs.

InMed Pharmaceuticals saw a significant increase in revenue from its BayMedica segment but continues to operate at a loss and faces substantial doubt about its ability to continue as a going concern.